Evidence map›Paper›PMID 33071527›Full record

ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2020

Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia.

Elizabeth Hewlett, Monika Toma, Katherine Sullivan-Reed, John Gordo, Tomasz Sliwinski, Alexei Tulin, Wayne E Childers, Tomasz Skorski

Open access · greenAbstract read
In one paragraph

Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Allosteric crosstalk in modular proteins: Function fine-tuning and drug design.Computational and structural biotechnology journal · 2023
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Elizabeth HewlettMoulder Center for Drug Discovery Research, Temple University School of Pharmacy, 3307 N. Broad Street, Philadelphia, PA, United States.
Monika TomaSol Sherry Thrombosis Research Center, Lewis Katz School of Medicine at Temple University, 3420 N. Broad Street, Philadelphia, PA, United States.
Katherine Sullivan-ReedSol Sherry Thrombosis Research Center, Lewis Katz School of Medicine at Temple University, 3420 N. Broad Street, Philadelphia, PA, United States.
John GordoMoulder Center for Drug Discovery Research, Temple University School of Pharmacy, 3307 N. Broad Street, Philadelphia, PA, United States.
Tomasz SliwinskiLaboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Alexei TulinSchool of Medicine and Health Sciences, University of North Dakota, 501 N. Columbia Rd., Grand Forks, ND, United States.
Wayne E ChildersMoulder Center for Drug Discovery Research, Temple University School of Pharmacy, 3307 N. Broad Street, Philadelphia, PA, United States.
Tomasz SkorskiSol Sherry Thrombosis Research Center, Lewis Katz School of Medicine at Temple University, 3420 N. Broad Street, Philadelphia, PA, United States.
Temple University · USUniversity of Łódź · PLUniversity of North Dakota · US

Funding

Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALLR01CA186238 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI SKORSKI, TOMASZ · 2014 to 2024
$4.5M
NCI NIH HHS R01 CA186238
6 · The paper itself

Abstract

The successful use of PARP1 inhibitors like olaparib (Loparza

Indexed as

AllostericBRCAHistone 4PARP1Synthetic Lethality

Identifiers

PMID33071527
PMCPMC7560981
OpenAlexW3019944982

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.